Identification of Nitric Oxide-Donating Lenumlostat Derivatives with Dual Activities of Extracellular Matrix Dysregulation Inhibition and Pulmonary Vasodilation for the Treatment of Pulmonary Arterial Hypertension
demonstrated superior efficacy in reducing right ventricular systolic pressure compared to lenumlostat. In short, the present study has demonstrated unequivocally that a therapeutic approach for PAH that combines NO donors for vasodilation with extracellular matrix inhibitors to suppress vascular remodeling represents a promising treatment.
Authors
- Liqing Hu (ORCID: https://orcid.org/0000-0003-3592-488X)
- S. Xiang
- Congke Zhao
- Y Hu
- Zhuo Chen (ORCID: https://orcid.org/0000-0002-5434-5747)
- Mengqi Li (ORCID: https://orcid.org/0000-0003-3894-5651)
- Wenhua Tan
- Bin Zeng
- Ruizhe Gao
- Xinru Liang
- Yu Wang
Institutions
- Central South University (CN)
- Hunan University (CN)
- Hunan Normal University (CN)
- Discovery Centre (CA)
- Buchang Pharma (China) (CN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-04-22
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c00665
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province